In compliance with the Ordinance on Drugs Tables, illegal handling of cannabis or cannabis products having an average THC amount of at least 1% is prohibited (OTStup-DFI, see link under "Legislation" ). However, some cannabis products, since they contain less than 1 percent THC, are not subject to the drug rule. Raw materials (flowers or hemp powder), refined products (oil or paste extracts, such as bulk capsules) or ready-to-use products, such as food supplements, can also be used. Sometimes sold as personal care products, e-cigarette liquids, nicotine substitutes, scent oils, chewing gums and ointments. The production and selling of these low THC goods has recently increased dramatically and poses a range of health and legal concerns. A variety of federal laws refer to their sale and advertisement, including, depending on the type of goods and their industrial exploitation: the law on medicinal products, the law on foodstuffs or the law on the protection of products. A notice to notify prospective suppliers about the legal structure has been drawn up by Swissmedic, the Federal Office of Public Health, the Federal Office for Food Safety and Veterinary Affairs and the Federal Office for Agriculture.
More than 80 cannabinoids and over 400 other substances are found in Hemp. Tetrahydrocannabinol (THC) and cannabidiol are the major cannabinoids (CBD). The above, which is not intoxicating, decreases the influence of THC on psychotropy. It is not subject to drug regulations. It is especially those with a high content of CBD that are gaining in importance among products with a low THC content. Supply and demand are increasingly growing. Currently, discussions concentrate on the potential therapeutic properties of CBD (antioxidants, anti-inflammatories, anticonvulsants, antiemetics, anxiolytics or antipsychotics). Research has not yet adequately proven its medicinal effect.